A phase 3 trial of nemvaleukin alfa in with Keytruda for patients with platinum-resistant ovarian cancer will not continue on ...

This study provides proof-of-principle data for the use of trained immunity to modulate macrophage interactions with tumours. The study makes a valuable contribution to the field of trained immunity.

Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science ...

Q4 2024 Earnings Call Transcript March 20, 2025 Monte Rosa Therapeutics, Inc. beats earnings expectations. Reported EPS is $0 ...

and those 10 years or older with homozygous familial hypercholesterolemia. BLA accepted for review Dupilumab (Regeneron and Sanofi) Interleukin-4 receptor alpha antagonist Treatment of adults with ...

Originally approved by the FDA in September 2023, Biogen's Tofidence became the first tocilizumab biosimilar available in the ...

Takeda boosts profit margins with AI-driven growth, FY2024 guidance upgrade, share buyback plan & promising drug launches.

Nemvaleukin alfa is an investigational engineered fusion protein composed of modified interleukin-2 (IL-2) and the high-affinity IL-2 alpha receptor chain.

Renier Brentjens, a CAR T-cell pioneer, views armored CAR T-cells as a promising avenue for treating solid tumors and ...

RedCloud and Marwynn Holdings have recently made their public debuts. The operator of a B2B platform for sellers of consumer goods in emerging ...